open access

Vol 72, No 5 (2021)
Review paper
Submitted: 2021-05-29
Accepted: 2021-07-17
Published online: 2021-08-04
Get Citation

Copeptin as a novel biomarker of cardiometabolic syndrome

Hanna Szmygin1, Joanna Szydełko1, Beata Matyjaszek-Matuszek1
DOI: 10.5603/EP.a2021.0072
·
Pubmed: 34378786
·
Endokrynologia Polska 2021;72(5):566-571.
Affiliations
  1. Department of Endocrinology, Diabetology, and Metabolic Disorders, Medical University of Lublin, Lublin, Poland

open access

Vol 72, No 5 (2021)
Review Article
Submitted: 2021-05-29
Accepted: 2021-07-17
Published online: 2021-08-04

Abstract

Arginine vasopressin (AVP), which is also called antidiuretic hormone (ADH), is a neurohormone synthetized from a pre-pro-hormone precursor in the supraoptic and paraventricular nuclei of the hypothalamus in response to increased plasma osmolality and decreased blood volume. AVP exerts several effects by binding to three different receptors: V1aR, V1bR, and V2R. In recent years, it has been suggested that increased plasma concentration of AVP may play a causal role in the development of type 2 diabetes, the metabolic syndrome, renal dysfunction and cardiovascular disease by influencing glucose homeostasis and lipid metabolism through several possible mechanisms involving V1aR and V1bR. V1aR located in the liver is involved in hepatic glycogenolysis and gluconeogenesis. V1bR, found in the pituitary gland and pancreas, mediates secretion of adrenocorticotrophic hormone (ACTH), insulin, and glucagon. However, AVP’s clinical use as a biomarker is limited due to its short half-life in plasma (16–20 minutes), small size, and poor stability, which make direct measurement difficult. Copeptin, the biologically inactive, stable, C-terminal part of pro-vasopressin, is co-secreted with AVP in equimolar amounts and thus is considered an adequate and clinically useful surrogate marker of AVP. The aim of this review is to assess the current state of knowledge about the potential role of copeptin as a novel biomarker of cardiometabolic syndrome on the basis of recent scientific literature published up to December 2020 and searches of the PubMed, Google Scholar, and Web of Science databases.

Abstract

Arginine vasopressin (AVP), which is also called antidiuretic hormone (ADH), is a neurohormone synthetized from a pre-pro-hormone precursor in the supraoptic and paraventricular nuclei of the hypothalamus in response to increased plasma osmolality and decreased blood volume. AVP exerts several effects by binding to three different receptors: V1aR, V1bR, and V2R. In recent years, it has been suggested that increased plasma concentration of AVP may play a causal role in the development of type 2 diabetes, the metabolic syndrome, renal dysfunction and cardiovascular disease by influencing glucose homeostasis and lipid metabolism through several possible mechanisms involving V1aR and V1bR. V1aR located in the liver is involved in hepatic glycogenolysis and gluconeogenesis. V1bR, found in the pituitary gland and pancreas, mediates secretion of adrenocorticotrophic hormone (ACTH), insulin, and glucagon. However, AVP’s clinical use as a biomarker is limited due to its short half-life in plasma (16–20 minutes), small size, and poor stability, which make direct measurement difficult. Copeptin, the biologically inactive, stable, C-terminal part of pro-vasopressin, is co-secreted with AVP in equimolar amounts and thus is considered an adequate and clinically useful surrogate marker of AVP. The aim of this review is to assess the current state of knowledge about the potential role of copeptin as a novel biomarker of cardiometabolic syndrome on the basis of recent scientific literature published up to December 2020 and searches of the PubMed, Google Scholar, and Web of Science databases.

Get Citation

Keywords

copeptin; AVP; metabolic syndrome; type 2 diabetes; cardiometabolic risk

About this article
Title

Copeptin as a novel biomarker of cardiometabolic syndrome

Journal

Endokrynologia Polska

Issue

Vol 72, No 5 (2021)

Article type

Review paper

Pages

566-571

Published online

2021-08-04

DOI

10.5603/EP.a2021.0072

Pubmed

34378786

Bibliographic record

Endokrynologia Polska 2021;72(5):566-571.

Keywords

copeptin
AVP
metabolic syndrome
type 2 diabetes
cardiometabolic risk

Authors

Hanna Szmygin
Joanna Szydełko
Beata Matyjaszek-Matuszek

References (57)
  1. Enhörning S, Tasevska I, Roussel R, et al. Effects of hydration on plasma copeptin, glycemia and gluco-regulatory hormones: a water intervention in humans. Eur J Nutr. 2019; 58(1): 315–324.
  2. Parizadeh SM, Ghandehari M, Parizadeh MR, et al. The diagnostic and prognostic value of copeptin in cardiovascular disease, current status, and prospective. J Cell Biochem. 2018; 119(10): 7913–7923.
  3. Guelinckx I, Vecchio M, Perrier ET, et al. Fluid Intake and Vasopressin: Connecting the Dots. Ann Nutr Metab. 2016; 68 Suppl 2: 6–11.
  4. Łukaszyk E, Małyszko J. Copeptin: Pathophysiology and potential clinical impact. Adv Med Sci. 2015; 60(2): 335–341.
  5. Enhörning S, Wang TJ, Nilsson PM, et al. Plasma copeptin and the risk of diabetes mellitus. Circulation. 2010; 121(19): 2102–2108.
  6. Rothermel J, Kulle A, Holterhus PM, et al. Copeptin in obese children and adolescents: relationships to body mass index, cortisol and gender. Clin Endocrinol (Oxf). 2016; 85(6): 868–873.
  7. Pikkemaat M, Melander O, Hjerpe P, et al. Prediction of treatment response in patients with newly diagnosed type 2 diabetes: the Skaraborg diabetes register. J Diabetes Complications. 2017; 31(5): 854–858.
  8. Abbasi A, Corpeleijn E, Meijer E, et al. Sex differences in the association between plasma copeptin and incident type 2 diabetes: the Prevention of Renal and Vascular Endstage Disease (PREVEND) study. Diabetologia. 2012; 55(7): 1963–1970.
  9. Saleem U, Khaleghi M, Morgenthaler NG, et al. Plasma carboxy-terminal provasopressin (copeptin): a novel marker of insulin resistance and metabolic syndrome. J Clin Endocrinol Metab. 2009; 94(7): 2558–2564.
  10. Pollard AD, Brindley DN. Effects of vasopressin and corticosterone on fatty acid metabolism and on the activities of glycerol phosphate acyltransferase and phosphatidate phosphohydrolase in rat hepatocytes. Biochem J. 1984; 217(2): 461–469.
  11. Enhörning S, Sjögren M, Hedblad Bo, et al. Genetic vasopressin 1b receptor variance in overweight and diabetes mellitus. Eur J Endocrinol. 2016; 174(1): 69–75.
  12. Widecka J, Ozegowska K, Banaszewska B, et al. Is copeptin a new potential biomarker of insulin resistance in polycystic ovary syndrome? Ginekol Pol. 2019; 90(3): 115–121.
  13. Enhörning S, Melander O. The Vasopressin System in the Risk of Diabetes and Cardiorenal Disease, and Hydration as a Potential Lifestyle Intervention. Ann Nutr Metab. 2018; 72 Suppl 2: 21–27.
  14. Melander O. Vasopressin, from Regulator to Disease Predictor for Diabetes and Cardiometabolic Risk. Ann Nutr Metab. 2016; 68 Suppl 2: 24–28.
  15. Thomsen C, Dreier R, Goharian T, et al. Association of copeptin, a surrogate marker for arginine vasopressin secretion, with insulin resistance: Influence of adolescence and psychological stress. Peptides. 2019; 115: 8–14.
  16. Morgenthaler N, Struck J, Alonso C, et al. Assay for the Measurement of Copeptin, a Stable Peptide Derived from the Precursor of Vasopressin. Clin Chem. 2006; 52(1): 112–119.
  17. Zellweger C, Wildi K, Twerenbold R, et al. Use of copeptin and high-sensitive cardiac troponin T for diagnosis and prognosis in patients with diabetes mellitus and suspected acute myocardial infarction. Int J Cardiol. 2015; 190: 190–197.
  18. Asferg CL, Andersen UB, Linneberg A, et al. Copeptin, a surrogate marker for arginine vasopressin secretion, is associated with higher glucose and insulin concentrations but not higher blood pressure in obese men. Diabet Med. 2014; 31(6): 728–732.
  19. Tasevska I, Enhörning S, Persson M, et al. Copeptin predicts coronary artery disease cardiovascular and total mortality. Heart. 2016; 102(2): 127–132.
  20. Salomaa V, Havulinna A, Saarela O, et al. Thirty-one novel biomarkers as predictors for clinically incident diabetes. PLoS One. 2010; 5(4): e10100.
  21. Ding C, Magkos F. Oxytocin and Vasopressin Systems in Obesity and Metabolic Health: Mechanisms and Perspectives. Curr Obes Rep. 2019; 8(3): 301–316.
  22. Enhörning S, Struck J, Wirfält E, et al. Plasma copeptin, a unifying factor behind the metabolic syndrome. J Clin Endocrinol Metab. 2011; 96(7): E1065–E1072.
  23. Enhörning S, Bankir L, Bouby N, et al. Copeptin, a marker of vasopressin, in abdominal obesity, diabetes and microalbuminuria: the prospective Malmö Diet and Cancer Study cardiovascular cohort. Int J Obes (Lond). 2013; 37(4): 598–603.
  24. Brunkwall L, Ericson U, Nilsson PM, et al. High water intake and low urine osmolality are associated with favorable metabolic profile at a population level: low vasopressin secretion as a possible explanation. Eur J Nutr. 2020; 59(8): 3715–3722.
  25. Vintilă M, Gheorghiu ML, Caragheorgheopol A, et al. Increased copeptin levels in metabolic syndrome from a Romanian population. J Med Life. 2016; 9(4): 353–357.
  26. Canivell S, Mohaupt M, Ackermann D, et al. Copeptin and insulin resistance: effect modification by age and 11 β-HSD2 activity in a population-based study. J Endocrinol Invest. 2018; 41(7): 799–808.
  27. Aktimur R, Mete T, Cetinkunar S, et al. Copeptin, a marker of vasopressin, decreases significantly in early state after bariatric surgery. Endocrine Abstracts. 2016.
  28. Taveau C, Chollet C, Waeckel L, et al. Vasopressin and hydration play a major role in the development of glucose intolerance and hepatic steatosis in obese rats. Diabetologia. 2015; 58(5): 1081–1090.
  29. Barchetta I, Enhörning S, Cimini FA, et al. Elevated plasma copeptin levels identify the presence and severity of non-alcoholic fatty liver disease in obesity. BMC Med. 2019; 17(1): 85.
  30. Enhörning S, Malan L. Copeptin relates to a fatty liver and measures of obesity in a South African population with mixed ethnicities. Endocrine. 2019; 65(2): 304–311.
  31. Jensen T, Bjornstad P, Johnson RJ, et al. Copeptin and Estimated Insulin Sensitivity in Adults With and Without Type 1 Diabetes: The CACTI Study. Can J Diabetes. 2019; 43(1): 34–39.
  32. Noor T, Hanif F, Kiran Z, et al. Relation of Copeptin with Diabetic and Renal Function Markers Among Patients with Diabetes Mellitus Progressing Towards Diabetic Nephropathy. Arch Med Res. 2020; 51(6): 548–555.
  33. Then C, Kowall B, Lechner A, et al. Plasma copeptin is associated with type 2 diabetes in men but not in women in the population-based KORA F4 study. Acta Diabetol. 2015; 52(1): 103–112.
  34. Popovic M, Ebrahimi F, Urwyler SA, et al. The role of IL-1 in the regulation of copeptin in patients with metabolic syndrome. Endocr Connect. 2020; 9(7): 715–723.
  35. Roussel R, El Boustany R, Bouby N, et al. Plasma Copeptin, AVP Gene Variants, and Incidence of Type 2 Diabetes in a Cohort From the Community. J Clin Endocrinol Metab. 2016; 101(6): 2432–2439.
  36. Potier L, Roussel R, Marre M, et al. Plasma Copeptin and Risk of Lower-Extremity Amputation in Type 1 and Type 2 Diabetes. Diabetes Care. 2019; 42(12): 2290–2297.
  37. Villela-Torres MD, Higareda-Mendoza AE, Gómez-García A, et al. Copeptin Plasma Levels are Associated with Decline of Renal Function in Patients with Type 2 Diabetes Mellitus. Arch Med Res. 2018; 49(1): 36–43.
  38. Zhu FX, Wu HL, Tu KS, et al. Serum levels of copeptin are associated with type 2 diabetes and diabetic complications in Chinese population. J Diabetes Complications. 2016; 30(8): 1566–1570.
  39. Enhörning S, Hedblad Bo, Nilsson PM, et al. Copeptin is an independent predictor of diabetic heart disease and death. Am Heart J. 2015; 169(4): 549–56.e1.
  40. Velho G, Ragot S, El Boustany R, et al. Plasma copeptin, kidney disease, and risk for cardiovascular morbidity and mortality in two cohorts of type 2 diabetes. Cardiovasc Diabetol. 2018; 17(1): 110.
  41. Boertien WE, Riphagen IJ, Drion I, et al. Copeptin, a surrogate marker for arginine vasopressin, is associated with declining glomerular filtration in patients with diabetes mellitus (ZODIAC-33). Diabetologia. 2013; 56(8): 1680–1688.
  42. Hu W, Ni YJ, Ma Li, et al. Serum copeptin as a new biomarker in the early diagnosis of decline in renal function of type 2 diabetes mellitus patients. Int J Clin Exp Med. 2015; 8(6): 9730–9736.
  43. Zhao Qi, Wu XX, Zhou J, et al. Elevated plasma levels of copeptin linked to diabetic retinopathy in type 2 diabetes. Mol Cell Endocrinol. 2017; 442: 106–112.
  44. Li B, Li Na, Guo S, et al. The changing features of serum adropin, copeptin, neprilysin and chitotriosidase which are associated with vascular endothelial function in type 2 diabetic retinopathy patients. J Diabetes Complications. 2020; 34(11): 107686.
  45. Riphagen IJ, Boertien WE, Alkhalaf A, et al. Copeptin, a surrogate marker for arginine vasopressin, is associated with cardiovascular and all-cause mortality in patients with type 2 diabetes (ZODIAC-31). Diabetes Care. 2013; 36(10): 3201–3207.
  46. Wannamethee SG, Welsh P, Papacosta O, et al. Copeptin, Insulin Resistance, and Risk of Incident Diabetes in Older Men. J Clin Endocrinol Metab. 2015; 100(9): 3332–3339.
  47. Smáradóttir MI, Catrina SB, Brismar K, et al. Copeptin and insulin-like growth factor binding protein-1 during follow-up after an acute myocardial infarction in patients with type 2 diabetes: A report from the Diabetes Mellitus Insulin-Glucose Infusion in Acute Myocardial Infarction 2 cohort. Diab Vasc Dis Res. 2019; 16(1): 22–27.
  48. Taskin MI, Bulbul E, Adali E, et al. Circulating levels of obestatin and copeptin in obese and nonobese women with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol. 2015; 189: 19–23.
  49. Muscogiuri G, Barrea L, Annunziata G, et al. Water intake keeps type 2 diabetes away? Focus on copeptin. Endocrine. 2018; 62(2): 292–298.
  50. Karbek B, Ozbek M, Karakose M, et al. Copeptin, a surrogate marker for arginine vasopressin, is associated with cardiovascular risk in patients with polycystic ovary syndrome. J Ovarian Res. 2014; 7: 31.
  51. Perrier E, Vergne S, Klein A, et al. Hydration biomarkers in free-living adults with different levels of habitual fluid consumption. Br J Nutr. 2013; 109(9): 1678–1687.
  52. Armstrong LE, Pumerantz AC, Fiala KA, et al. Human hydration indices: acute and longitudinal reference values. Int J Sport Nutr Exerc Metab. 2010; 20(2): 145–153.
  53. Dennis EA, Dengo AL, Comber DL, et al. Water consumption increases weight loss during a hypocaloric diet intervention in middle-aged and older adults. Obesity (Silver Spring). 2010; 18(2): 300–307.
  54. Chan J, Knutsen SF, Blix GG, et al. Water, other fluids, and fatal coronary heart disease: the Adventist Health Study. Am J Epidemiol. 2002; 155(9): 827–833.
  55. Enhörning S, Brunkwall L, Tasevska I, et al. Water Supplementation Reduces Copeptin and Plasma Glucose in Adults With High Copeptin: The H2O Metabolism Pilot Study. J Clin Endocrinol Metab. 2019; 104(6): 1917–1925.
  56. Roussel R, Fezeu L, Bouby N, et al. D.E.S.I.R. Study Group. Low water intake and risk for new-onset hyperglycemia. Diabetes Care. 2011; 34(12): 2551–2554.
  57. Stookey JD, Constant F, Popkin BM, et al. Drinking water is associated with weight loss in overweight dieting women independent of diet and activity. Obesity (Silver Spring). 2008; 16(11): 2481–2488.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl